Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease

Aducanumab is a human immunoglobulin G1 anti‐amyloid beta (Aβ) antibody currently being evaluated for potential treatment of patients with early Alzheimer’s disease. This paper describes the relationship between the population pharmacokinetics (PopPKs) and pharmacokinetics‐pharmacodynamics (PKs‐PDs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandadi Muralidharan, Kumar, Tong, Xiao, Kowalski, Kenneth G., Rajagovindan, Raj, Lin, Lin, Budd Haberlain, Samantha, Nestorov, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752104/
https://www.ncbi.nlm.nih.gov/pubmed/34697913
http://dx.doi.org/10.1002/psp4.12728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752104/
https://www.ncbi.nlm.nih.gov/pubmed/34697913
http://dx.doi.org/10.1002/psp4.12728

Ejemplares similares